88IV - Public company info - HBM Holdings Limited

Input the stock code or the company name

Search

Financial Ratios

HBM Holdings Limited, 02142.HK - Company Profile
Chairman	Jingsong Wang
Share Issued (share)	768,000,000
Par Currency	U.S. Dollar
Par Value	2.5E-5
Industry	Biotechnology
Corporate Profile	Business Summary: The group is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Performance for the year: The group’s operating loss was US$34.6 million, US$67.5 million and US$48.4 million for the years ended 31 December 2018 and 2019 and for the six months ended 30 June 2020, respectively. Business Review As of the Latest Practicable Date, the group had a diversified and balanced pipeline of more than ten potentially differentiated drug candidates, among which batoclimab (The group’s Core Product), tanfanercept (The group’s Core Product) and HBM4003 are in clinical development stage. Batoclimab and tanfanercept were in-licensed from HanAll and were not generated from the group’s Harbour antibody platforms. The group’s Harbour antibody platforms – HCAb Platform, HBICETM Platform and H2L2 Platform – constitute what the group believe to be a comprehensive technology solution1 available for discovering the next generation of fully human antibody therapeutics. the group’s HCAb Platform is a human antibody platform that engineers “heavy chain only” antibodies (HCAb) in a wide variety of formats (such as nanobodies, bispecific or multispecific antibodies and CAR-T) and with favorable developability. Leveraging the technology know-how the group accumulated on the group’s HCAb Platform, the group have independently developed the HBICETM Platform, which focuses on generating differentiated HCAb-based bispecific immune cell engagers potentially capable of delivering tumor-killing effects unachievable by combination therapies. the group’s H2L2 Platform generates, at a rapid rate and in a scalable fashion, classical two heavy and two light immunoglobulin chain antibodies (H2L2) with optimized fully human variable regions, allowing for endogenous affinity maturation and immune effector function. the group have exclusively in-licensed the worldwide rights for the group’s H2L2 Platform and HCAb Platform from Erasmus University Medical Center Rotterdam Department of Cell Biology, Erasmus MC Holding B.V., and Roger Kingdon Craig. the group’s Harbour antibody platforms are equipped with a suite of technologies that optimize or augment the therapeutic activity of antibodies, including important technology expansions for developing “heavy chain only” antibodies (HCAb), which is the group’s HCAb Platform, and for developing differentiated HCAb-based bispecific immune cell engagers potentially capable of delivering tumor-killing effects unachievable by combination therapies, which is the group’s HBICETM Platform. The group is committed to investing in the group’s platforms, generating new therapeutics and developing them into products that address significant unmet medical needs. the group’s Harbour antibody platforms have been validated by over 45 industry and academic partners with six projects having entered clinical stage as of 30 June 2020. Built upon the group’s strong track record of collaborations, the group believe the group’s Harbour antibody platforms will provide revenue creation potential and broaden the scope of the group’s development efforts. the group own global rights to use and develop the group’s Harbour antibody platforms, enabling us to maximize the value of the group’s platforms to address global unmet medical needs. Highlights of the group’s Immunology Portfolio The group’s immunology portfolio includes strategically selected, in-licensed, potentially differentiated clinical assets with near-term revenue potential targeting diseases with high unmet need. Batoclimab (HBM9161) and tanfanercept (HBM9036) are the group’s Core Products, and both of them are well positioned as the first mover to address significant unmet needs in their respective addressable markets in China. Batoclimab and tanfanercept were in-licensed from HanAll and were not generated from the group’s Harbour antibody platforms. Highlights of the group’s Immuno-Oncology Portfolio The group’s immuno-oncology portfolio includes mostly internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors. the group’s Harbour antibody platforms provide the foundation for this portfolio. HBM4003 is the anchor asset of this portfolio. Prospects: The group’s vision is to bring innovative medicines for healthy life. the group’s mission is to become a leading company driving innovation of next generation therapeutics. the group intend to achieve this by leveraging the group’s Harbour mice technologies to design innovative molecules against a variety of drug candidate targets. the group also aim to maximize the value of the group’s technology platform both internally and with the group’s partners across the world. Set forth below are the key elements of the group’s strategies: • Rapidly advance clinical programs to seek regulatory approval and commercialization of the group’s late-stage clinical assets, batoclimab (HBM9161) and tanfanercept (HBM9036), in China • Continue to develop and advance immuno-oncology differentiated molecules, including HBM4003, HBM7020 and HBM7008, among others, by utilizing the group’s next generation technology platforms • Maximize the value of the group’s Harbour antibody platforms through the group’s extensive network and collaborations • Continue to upgrade the group’s antibody platform technologies to consistently and repeatedly provide the tools to design and develop differentiated molecules • Build a fully integrated biopharmaceutical platform with manufacturing and commercialization capabilities

Information from the financial statements of listed companies

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2024

Suntek Computer Systems Limited.

All rights reserved